Back to results
US 2018/0291043 A1Published application
Benzocyclooctene-based and indene-based anticancer agents
AssigneeBaylor University
InventorsKevin G. PINNEY, Christine A. HERDMAN, Rajendra P. TANPURE, Zhi CHEN
Life of this patent
Estimating the term…
Abstract
Benzocyclooctene (fused 6,8 ring system) analogues and corresponding indene (fused 6,5 ring system) analogues function as inhibitors of tubulin polymerization. The compounds are useful as anticancer agents in a new therapeutic approach for cancer treatment utilizing small-molecule inhibitors of tubulin polymerization that also act as vascular disrupting agents (VDAs).
Claims9
A method of treating a vascular proliferative disorder in a subject, comprising:
- administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of a benzocyclooctene compound demonstrating inhibition of tubulin polymerization and having a structure of:
- wherein A is a bond, C═O, C═NH, or C═NR1, where R1 is any alkyl, aryl, or alkaryl substituent,
- B is CH2, NH, O, S, CH—OH, or CH—OR2, wherein R2 is CH3, or PO3−, or C—Z, wherein Z is halogen, and
- D is CH, N, C—OH, or C—OR3, wherein R3 is CH3, any alkyl substituent, any alkoxy substituent, any alkyl or alkoxy substituent including heteroatoms, any carbonyl substituent, any ester substituent, or PO3− or C—Z, wherein Z is halogen, and
- wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, adjuvant, carrier, buffer, stabilizer, or mixture thereof.
2 more elements
A method of inhibiting tubulin polymerization in a subject, comprising:
- administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of a benzocyclooctene compound demonstrating inhibition of tubulin polymerization and having a structure of:
- wherein A is a bond, C═O, C═NH, or C═NR1, where R1 is any alkyl, aryl, or alkaryl substituent,
- B is CH2, NH, O, S, CH—OH, or CH—OR2, wherein R2 is CH3, or PO3−, or C—Z, wherein Z is halogen, and
- D is CH, N, C—OH, or C—OR3, wherein R3 is CH3, any alkyl substituent, any alkoxy substituent, any alkyl or alkoxy substituent including heteroatoms, any carbonyl substituent, any ester substituent, or PO3− or C—Z, wherein Z is halogen, and
- wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, adjuvant, carrier, buffer, stabilizer, or mixture thereof.
2 more elements
Dependencies are inferred from the claim text.